Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
Post Operative Nausea and Vomiting, Sleeve Gastrectomy, Morbid Obesity
About this trial
This is an interventional prevention trial for Post Operative Nausea and Vomiting focused on measuring Postoperative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy, ondansetron, gabapentine
Eligibility Criteria
Inclusion Criteria: Both male and female patients will be included. Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the presence of comorbidity such as hypertension, arthritis, and diabetes. Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without comorbidity. Patients fit for anesthesia and surgery. Exclusion Criteria: - Patients with BMI >55 kg/m2. Patients with previous procedures for the treatment of obesity. Pregnant females and lactating women. Patients with psychological or psychiatric disease Administration of antiemetic medication or systemic corticosteroids within 24 hours before surgery Patients who experienced vomiting within 24 hours before surgery. Patients with history of alcohol or drug abuse. Patients with hypersensitivity or contraindications to any of the drugs used in this study.
Sites / Locations
- Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, EgyptRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group 1
Group 2
include 50 patients scheduled for sleeve gastrectomy
include 50 patients scheduled for sleeve gastrectomy